In combination with 5-fluorouracil, leucovorin, irinotecan- and headache. (FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC).
Therapeutic Class Cytotoxic Chemotherapy
Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.
4 mg/kg as an intravenous infusion over 1 hour every 2 weeks. ? Pregnancy: Based on animal data, it may cause fetal harm. ? Do not administer as an intravenous (IV) push or bolus
No dedicated drug-drug interaction studies have been conducted for Aflibercept. No clinically important pharmacokinetic drug-drug interactions were found between ziv-aflibercept and irinotecan/SN-38 or 5-FU, based on cross-study comparisons and population pharmacokinetic analyses.
leukopenia, diarrhea, neutropenia, proteinuria, AST increased, stomatitis, fatigue, thrombocytopenia, ALT increased, hypertension, weight decreased, decreased
Pregnancy: Based on animal data, it may cause fetal harm. ? Do not administer as an intravenous (IV) push or bolus. ? Nursing Mothers: Discontinue drug or nursing taking into account the importance of the drug to the mother.
There have been no cases of overdose reported with Aflibercept. There is no information on the safety of Aflibercept given at doses exceeding 7 mg per kg every 2 weeks or 9 mg per kg every 3 weeks.
Store Aflibercept vials in a refrigerator at 2 to 8° C . Keep the vials in the original outer carton to protect from light.
.png&w=384&q=75)